Available online at: (Accessed June 15, 2025)
The Blue Revolution begins soon
Disclosures: Wei Zhang: Nothing to Disclose, Ana Ivkovic: Nothing to Disclose, Kimberly Schoener: Nothing to Disclose, Kelly Hsu: Nothing to Disclose, Sienna Li: Nothing to Disclose, Samantha Nunes: Nothing to Disclose, KIMBERLY SULLIVAN: Nothing to Disclose, Emily Bethea: Nothing to Disclose, Heidi Yeh: Nothing to Disclose 1313 INCIDENCE AND OUTCOME OF REJECTION IN HYPERIMMUNIZED LIVER TRANSPLANT RECIPIENTS RECEIVING AN INDUCTION THERAPY Faouzi Saliba 1 Nada El-Domiaty 2 lea Duhaut 1 Audrey Coilly 1 Eleonora De Martin 1 Sophie-Caroline Sacleux 1 Wafaa Ibrahim 3 Philippe Ichai 1 Gabriella Pittau 1 Oriana Ciacio 1 Chady Salloum 1 Daniel Azoulay 1 Eric Vibert 1 Ren Adam 1 Jean Luc Taupin 4 Mylene Sebagh 1 Daniel Cherqui 1 Didier Samuel 1 , 1 AP-HP Hpital Paul Brousse, 2 Hpital Paul Brousse& Helwan university, 3 Cairo University, 4 Groupe Hospitalier St-Louis Lariboisire Background: Liver transplantation (LT) for hyperimmunized recipients with positive crossmatch or with preformed Donor specific antibodies (pDSA) present a unique challenge due to increased risk of antibody-mediated rejection (ABMR) and graft failure
For ED, the logic follows that a more localized administration could better target the intricate network of blood vessels and nerves within the pelvic region
Model selection was based on the Akaike information criterion (AIC), objective function (2 log- likelihood, 2LL), diagnostic plots, and parameter estimation uncertainty
5-amino-1MQ 30 , ,
